Things to look for in the New Year
Perhaps the biggest Alzheimer’s news in 2021 was the controversial FDA approval of the anti-amyloid monoclonal antibody Aduhelm (aducanumab). Controversy surrounds the mixed results of two parallel phase 3 trials. Both trials showed efficacy at removing...
Recent Comments